SPY741.76+0.88%QQQ661.95+0.89%BTC/USD74,571.28−0.21%DIA518.05+1.14%GLD377.82+1.42%TLT82.09+0.21%

Premium Services

Cellectis SA

CLLSNASDAQ

Trade with Public

Trade with Public

$1.07

0.043.88%

Last update: Nov 6, 4:17 PM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Cellectis (CLLS) Stock Price Target 2026

The average analyst price target for Cellectis is $6.47, 533.6% above the current price. Of 6 analysts, 4 rate it Buy, 1 Hold and 1 Sell. Targets range from $1.30 to $10. The latest change came on Sep 16, 2026, when Barclays downgraded Cellectis from Overweight to Underweight and moved its price target from $9 to $1.30.

The Average Analyst Price Target for Cellectis is $6.47.

Price Target Range — 6 Quarters

Analyst Consensus — 6 Analysts

1S.Buy

3Buy

1Hold

1Sell

Consensus RatingOutperform# Analysts6Avg. Consensus PT$6.47Upside to Avg. PT+533.6%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Cellectis Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 16, 2026	Barclays	Lukas Shumway	Downgrade	Overweight→Underweight	$9→$1
Sep 15, 2026	Wells Fargo	Yanan Zhu	PT Cut	Equal-Weight	$4→$3
Sep 15, 2026	Baird	Jack Allen	PT Cut	Outperform	$10→$8
Sep 15, 2026	Citizens	Silvan Turkcan	Downgrade	Market Outperform→Market Perform	—
May 28, 2026	Barclays	Lukas Shumway	Initiate	Overweight	$9
Apr 14, 2026	Citizens	Silvan Turkcan	Maintained	Market Outperform	$8
Dec 23, 2025	Clear Street	Bill Maughan	Initiate	Buy	$9
Oct 17, 2025	Barclays	Gena Wang	PT Raise	Overweight	$4→$8
May 13, 2025	Barclays	Gena Wang	PT Cut	Overweight	$5→$4
Nov 5, 2024	Barclays	Gena Wang	PT Cut	Overweight	$7→$5
Jun 12, 2024	Oppenheimer	Hartaj Singh	PT Cut	Outperform	$11→$10
May 31, 2024	JMP Securities	Silvan Tuerkcan	Maintained	Market Outperform	$6

Analyst Ratings News

This Nu Holdings Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday

Analysts downgraded NU, BAK, CLLS and CBZ; price targets for NU, BAK and CLLS were cut sharply.

Avi Kapoor

Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday

Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with several rating upgrades and downgrades.

Avi Kapoor

PRO
Barclays Downgrades Cellectis to Underweight, Lowers Price Target to $1.3

Barclays analyst Lukas Shumway downgrades Cellectis (NASDAQ:CLLS) from Overweight to Underweight and lowers the price target from $9 to $1.3.

Benzinga Newsdesk

This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Analysts downgraded Banco Santander Brasil, Ribbon Communications, Cellectis, Scholar Rock, with mixed price-target changes.

Avi Kapoor

PRO
Wells Fargo Maintains Equal-Weight on Cellectis, Lowers Price Target to $3

Wells Fargo analyst Yanan Zhu maintains Cellectis (NASDAQ:CLLS) with a Equal-Weight and lowers the price target from $4 to $3.

Benzinga Newsdesk

PRO
Baird Maintains Outperform on Cellectis, Lowers Price Target to $8

Baird analyst Jack Allen maintains Cellectis (NASDAQ:CLLS) with a Outperform and lowers the price target from $10 to $8.

Benzinga Newsdesk